Abstract
The incidence and severity of acute kidney injury (AKI) is rising globally, and the associated morbidity and mortality remain high despite promising advances in experimental therapeutics. The reasons include (a) an incomplete understanding of the complex pathophysiology, (b) an inability to reliably identify risk factors for AKI and (c) a lack of biomarkers for the early prediction of AKI and its outcomes. Functional genomics, bioinformatics and proteomics have begun to uncover candidates that are emerging as biomarkers and therapeutic targets. This review will update the reader on current technologies in genomics (including targeted sequencing, genome wide association studies and transcriptome profiling) and proteomics (including gel electrophoresis and mass spectrometry methods) and their application on human AKI.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.